Lakewood-Amedex Biotherapeutics, Inc.
LABT
$3.14
-$0.34-9.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 33.93% | -53.37% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.53% | -62.13% | |||
| Operating Income | -24.53% | 62.13% | |||
| Income Before Tax | -23.95% | 60.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.95% | 60.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.95% | 60.94% | |||
| EBIT | -24.53% | 62.13% | |||
| EBITDA | -24.57% | 62.17% | |||
| EPS Basic | 48.40% | -43.36% | |||
| Normalized Basic EPS | -23.95% | 61.10% | |||
| EPS Diluted | 48.40% | -43.36% | |||
| Normalized Diluted EPS | -23.95% | 61.10% | |||
| Average Basic Shares Outstanding | -0.01% | 0.40% | |||
| Average Diluted Shares Outstanding | -0.01% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||